These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Recent advances in the biochemistry and genetics of sphingolipidoses. Ozkara HA Brain Dev; 2004 Dec; 26(8):497-505. PubMed ID: 15533650 [TBL] [Abstract][Full Text] [Related]
10. [Enzyme replacement therapy in Pompe's disease]. Merk T; Wibmer T; Schumann C; Krüger S Med Klin (Munich); 2007 Jul; 102(7):570-3. PubMed ID: 17634875 [TBL] [Abstract][Full Text] [Related]
11. [Lysosomal storage diseases - update and new therapeutic options]. Schöpfer K; Miebach E; Beck M; Pitz S Klin Monbl Augenheilkd; 2011 Feb; 228(2):144-60. PubMed ID: 20309790 [TBL] [Abstract][Full Text] [Related]
12. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. Wilcox WR J Pediatr; 2004 May; 144(5 Suppl):S3-14. PubMed ID: 15126978 [No Abstract] [Full Text] [Related]
13. Mass spectrometry in the study of lysosomal storage disorders. Meikle PJ; Fuller M; Hopwood JJ Cell Mol Biol (Noisy-le-grand); 2003 Jul; 49(5):769-77. PubMed ID: 14528914 [TBL] [Abstract][Full Text] [Related]
14. Pathogenic mechanisms in lysosomal disease: a reappraisal of the role of the lysosome. Walkley SU Acta Paediatr; 2007 Apr; 96(455):26-32. PubMed ID: 17391436 [TBL] [Abstract][Full Text] [Related]
15. Storage solutions: treating lysosomal disorders of the brain. Jeyakumar M; Dwek RA; Butters TD; Platt FM Nat Rev Neurosci; 2005 Sep; 6(9):713-25. PubMed ID: 16049428 [TBL] [Abstract][Full Text] [Related]
16. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse. Virta S; Rapola J; Jalanko A; Laine M J Gene Med; 2006 Jun; 8(6):699-706. PubMed ID: 16518877 [TBL] [Abstract][Full Text] [Related]
18. Current strategies in the management of lysosomal storage diseases. Heese BA Semin Pediatr Neurol; 2008 Sep; 15(3):119-26. PubMed ID: 18708002 [TBL] [Abstract][Full Text] [Related]
19. A potentially dynamic lysosomal role for the endogenous TRPML proteins. Zeevi DA; Frumkin A; Offen-Glasner V; Kogot-Levin A; Bach G J Pathol; 2009 Oct; 219(2):153-62. PubMed ID: 19557826 [TBL] [Abstract][Full Text] [Related]
20. Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. Giugliani R; Vairo F; Kubaski F; Poswar F; Riegel M; Baldo G; Saute JA Lancet Child Adolesc Health; 2018 Jan; 2(1):56-68. PubMed ID: 30169196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]